Cambridge, MA ; 03/13/2020
Amount Funded: $102 Million
Type: Series C
Lead Investor: Biotechnology Value Fund, Redmile Group
Participating Investor(s): Wellington Management Company, Bain Capital Life Sciences, Janus Henderson Investors, BlackRock, Springs Capital, others
Company Description: Kymera Therapeutics is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Powered by Pegasus™, a game-changing integrated degradation platform, Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients.
What funding will be used for: Advancing its Protein Degrader pipeline and platform
“We are very excited to be joined by a top-tier group of investors as we continue on our path to become a fully integrated biotech company,. We are well capitalized to advance up to three programs to the clinic by next year, while we continue to enhance our best-in-class platform to unlock new biology and invent new medicines.”
-Nello Mainolfi, PhD, co-founder/President/CEO, Kymera Therapeutics
Data provided by respective company (unless otherwise noted) and researched by StartupsOne for accuracy.